Prevalence and Indicators of Viral Suppression Among Persons With Diagnosed HIV Infection Retained in Care -- Georgia, 2010

Characteristic

Persons with diagnosed HIV

Viral suppression

No.

%

No.

%

Overall

1,340

100.0

958

71.5

Race/Ethnicity

Black

720

53.7

456

63.3

White

149

11.1

116

78.2

Hispanic

78

5.8

61

77.9

Other/Unknown

393

29.3

325

82.7

Age group (yrs)^§

13-24

255

19.0

144

56.5

25-34

366

27.3

258

70.5

35-44

307

22.9

229

74.6

45-54

290

21.6

228

78.6

≥55

122

9.0

99

81.2

Disease stage at diagnosis^¶

1

211

15.8

136

64.5

2

336

25.1

243

72.3

3

375

28.0

302

80.5

Unknown

418

31.2

277

66.3

Transmission category**

Male

1,033

77.1 (100.0)

740

71.6

Male-to-male sexual contact

638

47.6 (61.7)

418

65.5

Injection drug use

30

2.3 (3.0)

20

65.3

Male-to-male sexual contact and injection drug use

15

1.1 (1.5)

10

66.7

Heterosexual contact

46

3.4 (4.4)

35

77.4

Other/Unknown^††

304

22.7 (29.4)

257

84.5

Female

307

22.9 (100.0)

218

71.0

Injection drug use

43

3.2 (13.4)

33

78.6

Heterosexual contact

208

15.6 (67.9)

142

67.9

Other/Unknown^††

56

4.2 (18.3)

43

76.8

* Retained in care defined as having at least two laboratory tests (CD4+ or viral load) at least 3 months apart during 4-15 months after diagnosis.

† Among persons residing in Georgia and having a positive Western Blot or viral load based on surveillance data reported during 2010. Viral suppression defined as viral load <200 on the basis of most recent test during 4-15 months after diagnosis. Only includes persons with their sex recorded at birth.

§ Age based on the person's age at year's end 2010.

¶ Based on first recorded CD4+ cell count ≤3 months after diagnosis. Defined as stage 1: CD4+ count ≥500 cells/µL or CD4+ percentage of total lymphocytes ≥29; stage 2: CD4+ count of 200-499 cells/µL or CD4+ percentage of total lymphocytes of 14-28; and stage 3: CD4+ count of <200 cells/µL or CD4+ percentage of total lymphocytes of <14.

** Data by transmission category have been statistically adjusted to account for missing transmission category. Nested percentages indicate percentages among newly diagnosed persons of specified sex.

†† Includes hemophilia, blood transfusion, perinatal exposure, or risk factor unknown or not indicated.

Characteristic

Prevalence ratio

(95% CI)

p value

Race/Ethnicity

Black

0.9

(0.8-0.9)

<0.01

White (reference group)

1.0

Hispanic

1.0

(0.9-1.2)

0.70

Other/Unknown

1.1

(1.0-1.2)

0.07

Age group (yrs)^§

13-24

0.8

(0.7-0.9)

<0.01

25-34

0.9

(0.7-1.0)

0.17

35-44

0.9

(0.8-1.0)

0.23

45-54

0.9

(0.9-1.1)

0.33

≥55 (reference group)

1.0

Disease stage at diagnosis^¶

1

0.8

(0.7-0.9)

<0.01

2

0.9

(0.8-1.0)

0.02

3 (reference group)

1.0

Unknown

0.8

(0.8-0.9)

<0.01

Sex

Male

1.0

Female

1.0

(0.9-1.1)

0.97

Abbreviation: CI = confidence interval.

* Retained in care defined as having at least two laboratory tests (CD4+ or viral load) at least 3 months apart during 4-15 months after diagnosis.

† Among persons residing in Georgia and having a positive Western Blot or viral load based on surveillance data reported during 2010. Viral suppression defined as viral load <200 on the basis of most recent test during 4-15 months after diagnosis. Only includes persons with their sex recorded at birth.

§ Age based on the person's age at year's end 2010.

¶ Based on first recorded CD4+ cell count ≤3 months after diagnosis. Defined as stage 1: CD4+ count ≥500 cells/µL or CD4+ percentage of total lymphocytes ≥29; stage 2: CD4+ count of 200-499 cells/µL or CD4+ percentage of total lymphocytes of 14-28; and stage 3: CD4+ count of <200 cells/µL or CD4+ percentage of total lymphocytes of <14.